Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECTION PLUS open-label extension of Dimebon in Alzheimer's disease
2008-006352-22Phase 3Terminated
- Sponsor
- Medivation
- Start
- Mar 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoint: Safety and tolerability of long-term dimebon treatment. Started Mar 2009; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-006352-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006352-22.